Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Apr 25;3(2):e000874. doi: 10.1161/JAHA.114.000874

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2014 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.

This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Figure 2. — Maraviroc (MVC) reduces viral replication in heart and plasma, and macrophage activation in myocardium. A, Simian immunodeficiency virus (SIV) RNA levels in the heart were significantly lower in MVC‐treated SIV‐infected macaques vs untreated SIV‐infected macaques. B, Mean plasma viral load over the course of infection in MVC‐treated vs untreated SIV‐infected macaques showed an initial 1 to 2 log decrease in SIV RNA. C, Total immunostaining for CD163+ macrophages was significantly lower in MVC‐treated vs untreated SIV‐infected macaques, similar to immunostaining levels in uninfected control macaques (see Figure 3). D, In contrast, MVC treatment did not reduce myocardial immunostaining for CD68 in SIV‐infected macaques. Mann‐Whitney; bars represent median values.